Selexipag
CAS 475086-01-2 8 FDA-DMF suppliersSmall Molecule
Overview
Selexipag is an oral selective IP prostacyclin receptor agonist used in the treatment of pulmonary arterial hypertension (PAH). It acts by relaxing the muscles in the walls of blood vessels to reduce the elevated pulmonary blood pressure to normal levels.
Patent & exclusivity (US)
Per the FDA Orange Book (23 approved US products), the latest listed US patent on Selexipag expires 31 May 2037. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Pulmonary HypertensionCardiovascular Diseases
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.